Celerion acquires early stage clinical research operations from MDS Pharma Services – Celerion #ciba #pharmaceuticals

Posted On Oct 24 2016 by

#mds pharma services # Celerion acquires early stage clinical research operations from MDS Pharma Services Celerion acquires early stage clinical research operations from MDS Pharma Services (Lincoln, NE, Mar 29, 2010) – Celerion, a privately owned contract research organization (CRO), has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical laboratories located in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Zurich, Switzerland; and Belfast, Northern Ireland, as well as operations in Richmond, Virginia and Quebec, Canada. With over 700 …


9 Investigates: Local doctors paid high sums from pharmaceutical companies #pharma #contract #manufacturing

Posted On Oct 23 2016 by

#pharmaceutical companies in charlotte nc # SIGN IN Sign Up / Sign In Sign Up / Sign In You’re Almost Done! REGISTER Thank you for registering! Thank you for registering! Create a new password Email sent Sign in to complete account merge Why are we asking this? Resend Email Verification Resend Email Verification Your Verification Email Has Been Sent 9 Investigates: Local doctors paid high sums from pharmaceutical companies CHARLOTTE, N.C. – New federal legislation will help state officials track which local doctors are getting paid big bucks from pharmaceutical companies. Those payments will be tracked through Medicaid. In less …


FDA bans imports from Sun Pharma plant in India crackdown #pharma #iq

Posted On Oct 23 2016 by

#sun pharma # FDA bans imports from Sun Pharma plant in India crackdown By Zeba Siddiqui and Sumeet Chatterjee | MUMBAI MUMBAI (Reuters) – The U.S. Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Sun Pharmaceutical Industries Ltd’s plant at Karkhadi in the western state of Gujarat, in the latest quality blow for India’s drug sector. The FDA has imposed a rash of regulatory sanctions on Indian generic makers in the last year, triggering concerns about the quality of the medicines supplied by the $14 billion industry to countries including the United States, the biggest market. …


Martin Shkreli Resigns From Turing Pharmaceuticals #pharma #career

Posted On Oct 23 2016 by

#pharmaceutical companies in nyc # The New York Times Martin Shkreli Resigns From Turing Pharmaceuticals By ANDREW POLLACK December 18, 2015 Martin Shkreli has resigned as chief executive of Turing Pharmaceuticals after his arrest on securities fraud charges, the company announced on Friday. Turing, a privately held company in New York, said that Ron Tilles. its chairman, would step in as interim chief executive. Mr. Tilles, who will remain chairman, has spent most of his career at securities firms and other financial service companies, according to the description of him on Turing’s website. But he was a founder and worked …


Healthcare business news, research, data and events from Modern Healthcare #the #drug #company

Posted On Oct 22 2016 by

#healthcare industry news #


Top 7 Healthcare Trends and Challenges from #par #pharma

Posted On Oct 22 2016 by

#healthcare industry news # Top 7 Healthcare Trends and Challenges from Our Financial Expert There are all kinds of facts, figures, and guesses floating around right now as to what are the top healthcare challenges and trends in 2015 … and beyond. I’ve thought about it and put together this list about what we can expect in the near future. Give it a look, and let me know if I’ve missed anything. 1. Physicians start to feel the financial pinch from CMS’s regulations. Value-based purchasing programs are solidly in place for hospitals. But now, eligible physicians are starting to feel …


Market Research Reports and Forecasts from BCC Research #jamjoom #pharma

Posted On Oct 7 2016 by

#market research reports # Market Research Reports & Reviews BCC Research publishes over 250 market research reports annually. Our reports provide 5-year market forecasts with important statistical and analytical information on the markets, applications, industry structure, major players, market shares, industry dynamics, technology and technology shifts, and international developments relevant to these critical markets. Readers get a highly key, forward-looking information on hard-to-find market intelligence and insights into complex issues that allow them to acquire a competitive edge, refine their strategic planning and identify business opportunities. Coverage of Advanced Materials related industries like ceramics, glass, metals, alloys, construction material and …


Market Research Reports and Industry Analysis from JSB Market Research #gold #pharma

Posted On Oct 6 2016 by

#market research reports # Market Research Reports and Industry Analysis JSB Market Research Pvt.Ltd was formed in 2013 and the portal www.jsbmarketresearch.com for quality primary market research reports was launched to dedicatedly provide quick search service to global clients with no restriction to any industry verticals. We favour timeliness of deliverables as one of the prime points of business in today’s competitive market research arena. For us, the process adds value to our core business. But, as a competing firm with, JSB Market Research Pvt.Ltd is equally aligned to providing quality reports to clients. Accelerating business prospects with our market …


Bill would prevent drug makers from thwarting generic competition #pharm

Posted On Oct 6 2016 by

#generic drug companies # Lawmakers look to prevent drug makers from thwarting generic competition For the third time in less than two years, congressional lawmakers have introduced a bill designed to end a practice that generic drug makers say is used by brand-name rivals to thwart competition. Known as the Creating and Restoring Equal Access to Equivalent Samples Act, the bipartisan legislation comes amid ongoing complaints that brand-name drug makers sometimes refuse to provide samples to generic companies. They need samples to prove their copycat versions are equivalent to the brand-name drugs in order to pass regulatory muster. And the …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #drug #company

Posted On Oct 6 2016 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …